Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
ANNOUNCEMENT ON THE PROGRESS OF ON-MARKET ACQUISITION OF H SHARES BY THE TRUSTEE

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

Reference is made to (i) the circular of the Company dated November 28, 2025 (the "**Circular**") and the poll results announcement of the Company dated December 17, 2025 in relation to, among other things, the approval by the Shareholders at the EGM of the adoption of the H Share Award Scheme; and (ii) the Company's voluntary announcement dated May 20, 2026 (the "**Announcement**") on the proposed on-market acquisition of H Shares by the Trustee in the amount of up to US$50 million under the H Share Award Scheme. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the H Share Award Scheme Rules, the Circular and the Announcement.

On November 16, 2026, the Trustee purchased 220,700 H Shares on The Stock Exchange of Hong Kong Limited under the H Share Award Scheme (the "**Share Purchase**") for an aggregate consideration of HK$7,372,606.

The Company may continue to instruct the Trustee to acquire H Shares through on-market transactions in accordance with the H Share Award Scheme Rules.

The Board believes that the Share Purchase demonstrates the Company's confidence in its business outlook and prospects and will, in the long term, benefit the Company and enhance value for its Shareholders. The Board further believes that the Company has sufficient financial resources to implement the Share Purchase while maintaining a solid financial position.

Shareholders and potential investors should note that any Share Purchase will be subject to market conditions and other factors, and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any Share Purchase, or whether or not the Company will make any Share Purchase at all. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Hong Kong, November 17, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.